Dr Grégory Guirimand

Pays: 
France
Programme: 
ARD 2020-BIOPHARMACEUTICALS
Scientific Field: 
Période: 
juin, 2019 au juin, 2020

LE STUDIUM RESEARCH FELLOW / ARD 2020 - BIOMÉDICAMENTS Programme

Établissement d'origine

École Supérieure des Sciences, de la Technologie et de l'Innovation, Université de Kobe - JP

Laboratoire d'accueil

Laboratoire Biomolécules et Biotechnologies Végétales (BBV), EA 2106, Université de Tours - FR

Hôte scientifiques

Dr Vincent Courdavault

PROJET

Bio-production of vindoline and catharanthine by recombinant yeast cell factories

The tropical plant Madagascar periwinkle (Catharanthus roseus) is naturally able to synthesize anti-cancer monoterpene indole alkaloids (MIA), such as vinblastine and vincristine. 

The C. roseus MIA biosynthetic pathway is however regarded as the most complex pathway in all living organisms and shows surprising compartmentation at both cellular and subcellular levels. This drastic compartmentation is potentially responsible for the extremely low level of production of MIA in planta

Our research project precisely aims to develop recombinant yeast cell factories in order to achieve heterologous bio-production of vindoline and catharanthine, two precursors of highly valuable anticancer MIA, originally produced by C. roseus

To achieve this goal, a combination of metabolic and cell surface engineering approaches, using cutting-edge tools of synthetic biology in backer’s yeast (Saccharomyces cerevisiae) will be used. 

figure 

Keywords: Anti-cancer compounds; Monoterpene Indole Alkaloids (MIA); secondary metabolites; traditional medicinal plants; yeast metabolic engineering; bio-reactor.